ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Abstract #980

Introduction: Somatostatin analogs (SSAs) are the mainstay treatment
Aim(s): ELECT evaluated rescue therapy use as a measure for LAN control of CS symptoms.
Materials and methods: Eligible pts had histologically-confirmed NET and a history of CS, and were SSA naïve or responsive to octreotide LAR ≤30mg/4wks or short-acting SC ≤600μg/day. Design: a 16wk randomized double-blind phase (LAN 120mg [n=59] v. placebo [n=56] every 4wks), and a 32wk open-label LAN extension. Pts had access to octreotide SC as rescue for breakthrough symptoms. Primary endpoint: % of days rescue used during double-blind phase. Study was designed to have 90% power to detect a 30% treatment difference. Double-blind phase results only are presented.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Edda Gomez-Panzani
Keywords: symptom control

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Alexandria T Phan
Keywords: Lanreotide, safety
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#325 Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results
Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Baudin
#1175 Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials
Introduction: LAN provide antitumor effects and symptom control in NET pts.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Nuria Buil-Bruna
Keywords: PK, dosing
#1193 Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-) NETs: Post Hoc Analyses from the CLARINET Study
Introduction: In CLARINET, favourable efficacy and safety with LAN in metastatic EP-NETs was associated with stable HRQoL outcomes.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...